Clinical Trials
53
Trial Phases
5 Phases
Drug Approvals
17
Drug Approvals
Calcium Polystyrene Sulfonate Powder
- Product Name
- 聚苯乙烯磺酸钙散剂
- Approval Number
- 国药准字HJ20150442
- Approval Date
- Oct 19, 2020
Calcium Polystyrene Sulfonate Powder
- Product Name
- 聚苯乙烯磺酸钙散剂
- Approval Number
- 国药准字HJ20150427
- Approval Date
- Oct 19, 2020
Calcium Polystyrene Sulfonate Powder
- Product Name
- 聚苯乙烯磺酸钙散剂
- Approval Number
- 国药准字HJ20150428
- Approval Date
- Oct 19, 2020
Calcium Polystyrene Sulfonate Powder
- Product Name
- 聚苯乙烯磺酸钙散剂
- Approval Number
- 国药准字HJ20150443
- Approval Date
- Oct 19, 2020
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (42 trials with phase data)• Click on a phase to view related trials
A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: K-877 0.4 mg/day (once daily)Drug: K-877 0.2 mg/day (once daily)Drug: Placebo (once daily)
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Kowa Company, Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05923281
- Locations
- 🇯🇵
Central Japan International Medical Center, Gifu, Japan
🇯🇵Kumamoto University Hospital, Kumamoto, Japan
🇯🇵Fukuwa Clinic, Tokyo, Japan
A Phase III Confirmatory Study of K-237
- Conditions
- Covid19
- Interventions
- Drug: Placebo 0.3-0.4mg/kg (once daily)Drug: K-237 0.3-0.4mg/kg (once daily)
- First Posted Date
- 2021-09-27
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Kowa Company, Ltd.
- Target Recruit Count
- 1030
- Registration Number
- NCT05056883
- Locations
- 🇯🇵
Hosokawa Surgical Clinic, Aichi, Japan
🇯🇵Nagoya City University West Medical Center, Aichi, Japan
🇯🇵Nagoya City University East Medical Center, Aichi, Japan
A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C
- Conditions
- Hyperlipidemia
- Interventions
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Kowa Company, Ltd.
- Target Recruit Count
- 353
- Registration Number
- NCT04998981
- Locations
- 🇨🇳
Huainan First People's Hospital, Anhui, China
🇨🇳Beijing Anzhen Hospital, Capital Medical University, Beijing, China
🇨🇳Beijing Hospital, Beijing, China
A Phase III Long Term Study of K-877 Extended Release Tablet
- Conditions
- Dyslipidemias
- Interventions
- Drug: K-877 ER 0.2 mg/day evening administration (once daily)Drug: K-877 ER 0.2 mg/day morning administration (once daily)
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Kowa Company, Ltd.
- Target Recruit Count
- 121
- Registration Number
- NCT04716595
- Locations
- 🇯🇵
Saiseikai Futsukaichi Hospital, Fukuoka, Japan
🇯🇵National Hospital Organization Takasaki General Medical Center, Gunma, Japan
🇯🇵Hasegawa Medicine Clinic, Hokkaido, Japan
A Phase III Confirmatory Study of K-877 Extended Release Tablet
- Conditions
- Dyslipidemias
- Interventions
- Drug: K-877 IR 0.2 mg/day (twice daily)Drug: K-877 ER 0.2 mg/day (once daily)Drug: K-877 ER 0.4 mg/day (once daily)
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Kowa Company, Ltd.
- Target Recruit Count
- 356
- Registration Number
- NCT04714151
- Locations
- 🇯🇵
Institute Medical Corporation Hitomikai Motomachi Takatsuka Naika Clinic, Kanagawa, Japan
🇯🇵Medical Corporation Heishinkai OCROM Clinic, Osaka, Japan
🇯🇵Dojinkinenkai Meiwa Hospital, Tokyo, Japan
- Prev
- 1
- 2
- 3
- Next